AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21180674 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic extract mouthwash (garlic extract + water + sorbitol + spearmint oil)
Number of subjects: 45
Study 21180674 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.2%) mouthwash
Number of subjects: 45
Study 21180674 — intervention group
Group type: COMPARATOR
Intervention: Negative control (water + sorbitol + spearmint oil)
Number of subjects: 45
Study 18635504 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia/analgesia supplementation
Number of subjects: 177
Study 18635504 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 177
Study 18635504 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 177
Study 18635504 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and hypertension interaction
Number of subjects: 177
Study 16360599 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 20
Study 16360599 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study 14668456 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug regimen containing didanosine, stavudine, nelfinavir, and efavirenz
Number of subjects: 980
Study 14668456 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug regimen containing zidovudine, lamivudine, nelfinavir, and efavirenz
Number of subjects: 980
Study 14668456 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-drug regimen
Number of subjects: 980
Study 14668456 — intervention group
Group type: COMPARATOR
Intervention: Three-drug regimen containing zidovudine, lamivudine, and efavirenz
Number of subjects: 980
Study 11077325 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen‐Rossetti total fundic wrap with intact short gastric vessels
Number of subjects: 99
Study 11077325 — intervention group
Group type: COMPARATOR
Intervention: Complete division of short gastric vessels
Number of subjects: 99
Study 11077325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures (intact vessels and division)
Number of subjects: 99
Study 11077325 — intervention group
Group type: COMPARATOR
Intervention: Division of short gastric vessels
Number of subjects: 99
Study 9024266 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human insulin-like growth factor I (rhIGF-I) at 120 micrograms/kg BW twice daily (n = 15)
Number of subjects: 22
Study 9024266 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human insulin-like growth factor I (rhIGF-I) at 80 micrograms/kg BW twice daily (n = 7)
Number of subjects: 22
Study 9024266 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (GH) treatment in idiopathic growth hormone deficiency (GHD) (n = 11)
Number of subjects: 22
Study 1563538 — intervention group
Group type: EXPERIMENTAL
Intervention: Random urine sample during outpatient visit
Number of subjects: 209
Study 1563538 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbumintest (Ames‐Bayer)
Number of subjects: 209
Study 3095080 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol electrolyte lavage solution
Number of subjects: 80
Study 3095080 — intervention group
Group type: COMPARATOR
Intervention: 10 percent mannitol solution
Number of subjects: 80
Study 29550780 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility plus community interventions
Number of subjects: 0
Study 29550780 — intervention group
Group type: COMPARATOR
Intervention: Facility-only interventions
Number of subjects: 0
Study 29550780 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Uganda only)
Number of subjects: 0
Study 27569033 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-lengthening of the transverse carpal ligament (TCL) according to a modified Simonetta technique
Number of subjects: 80
Study 27569033 — intervention group
Group type: COMPARATOR
Intervention: Complete release of the transverse carpal ligament (TCL)
Number of subjects: 80
Study 27569033 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Z-lengthening and complete release)
Number of subjects: 80
Study 24907721 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 62
Study 24907721 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 62
Study 22037389 — intervention group
Group type: EXPERIMENTAL
Intervention: DNR order
Number of subjects: 375
Study 22037389 — intervention group
Group type: COMPARATOR
Intervention: Full Code order
Number of subjects: 375
Study 20356687 — intervention group
Group type: EXPERIMENTAL
Intervention: Early salvage hormonal therapy (HT) initiated with PSA < 10 ng/mL
Number of subjects: 0
Study 20356687 — intervention group
Group type: COMPARATOR
Intervention: Late salvage hormonal therapy (HT) initiated with PSA ≥ 10 ng/mL
Number of subjects: 0
Study 17942524 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN-beta) treatment
Number of subjects: 56
Study 17942524 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated MS patients)
Number of subjects: 56
Study 19742086 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine and 5% prilocaine cream (Emla Astra)
Number of subjects: 0
Study 19742086 — intervention group
Group type: COMPARATOR
Intervention: 50% diluted Citanest solution with ring-type infiltration
Number of subjects: 0
Study 15804789 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming (water therapy)
Number of subjects: 377
Study 15804789 — intervention group
Group type: COMPARATOR
Intervention: Bathing (control)
Number of subjects: 377
Study 12127196 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment abstainers
Number of subjects: 142
Study 12127196 — intervention group
Group type: COMPARATOR
Intervention: Non-abstainers
Number of subjects: 142
Study 9129588 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin plus lansoprazole
Number of subjects: 104
Study 9129588 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 104
Study 8188164 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal conditions for serum specimen preparation (immediate centrifugation after clot formation)
Number of subjects: 0
Study 8188164 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugation through a paraffin plug (serum separator tube)
Number of subjects: 0
Study 8188164 — intervention group
Group type: EXPERIMENTAL
Intervention: Three freeze-thaw cycles
Number of subjects: 0
Study 8188164 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative branched DNA signal amplification assay under optimal conditions
Number of subjects: 0
Study 8188164 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluctuations in hepatitis C virus RNA levels
Number of subjects: 0
Study 3683478 — intervention group
Group type: COMPARATOR
Intervention: Bilateral myringotomy (Group 1)
Number of subjects: 578
Study 3683478 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of tympanostomy tubes (Group 2)
Number of subjects: 578
Study 3683478 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy (Group 3)
Number of subjects: 578
Study 3683478 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy and placement of tympanostomy tubes (Group 4)
Number of subjects: 578
Study 3683478 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups 2, 3, and 4
Number of subjects: 578
Study 3683478 — intervention group
Group type: COMPARATOR
Intervention: Group 1
Number of subjects: 578
Study 3683478 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2
Number of subjects: 578
Study 3683478 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3
Number of subjects: 578
Study 3683478 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4
Number of subjects: 578
Study 3683478 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy plus bilateral myringotomy
Number of subjects: 578
Study 12629094 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 4 IU/m².d (approximately 0.045 mg/kg/d)
Number of subjects: 60
Study 12629094 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: first year 4 IU/m².d; thereafter 6 IU/m².d
Number of subjects: 60
Study 12629094 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: first year 4 IU/m².d; second year 6 IU/m².d; thereafter 8 IU/m².d
Number of subjects: 60
Study 12629094 — intervention group
Group type: COMPARATOR
Intervention: Group A vs Group B
Number of subjects: 60
Study 12629094 — intervention group
Group type: COMPARATOR
Intervention: Group A vs Group C
Number of subjects: 60
Study 12629094 — intervention group
Group type: COMPARATOR
Intervention: Group B vs Group C
Number of subjects: 60
Study 12629094 — intervention group
Group type: EXPERIMENTAL
Intervention: After starting estrogen treatment
Number of subjects: 60
Study 12629094 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 60
Study 29625440 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Number of subjects: 660
Study 29625440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 660
Study 29625440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg)
Number of subjects: 660
Study 29625440 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept, Bevacizumab, Ranibizumab
Number of subjects: 660
Study 27543470 — intervention group
Group type: EXPERIMENTAL
Intervention: Early direct current cardioversion (DCCV) and oral Amiodarone for 6 weeks (Group 2)
Number of subjects: 35
Study 27543470 — intervention group
Group type: COMPARATOR
Intervention: Successful balloon mitral valvotomy (PBMV) alone (Group 1)
Number of subjects: 35
Study 24886701 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine
Number of subjects: 30
Study 24886701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22868212 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 μg/kg NMC
Number of subjects: 13
Study 22868212 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg NMC
Number of subjects: 13
Study 22868212 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 μg/kg NMC
Number of subjects: 13
Study 22868212 — intervention group
Group type: EXPERIMENTAL
Intervention: 50.0 μg/kg NMC
Number of subjects: 13
Study 22868212 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 μg/kg GRP
Number of subjects: 13
Study 22868212 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg NMC + 20.0 μg/kg [d‐Lys(3)]‐GHRP‐6
Number of subjects: 13
Study 22868212 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg NMC + 20.0 μg/kg N‐GRP‐EE
Number of subjects: 13
Study 22868212 — intervention group
Group type: EXPERIMENTAL
Intervention: 20.0 μg/kg N‐GRP‐EE
Number of subjects: 13
Study 22868212 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg NMB
Number of subjects: 13
Study 22868212 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg NMC in pre-weaned calves
Number of subjects: 13
Study 22868212 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg NMC in rats
Number of subjects: 13
Study 21126666 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of warm fluids at 37° C
Number of subjects: 30
Study 21126666 — intervention group
Group type: COMPARATOR
Intervention: Infusion of room temperature fluids
Number of subjects: 30
Study 19079957 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg oral cabergoline per day for 3 weeks beginning on the day after oocyte retrieval
Number of subjects: 166
Study 19079957 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 166
Study 15690266 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine 10 mg
Number of subjects: 8
Study 15690266 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine 20 mg
Number of subjects: 8
Study 15690266 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine 30 mg
Number of subjects: 8
Study 15690266 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine 40 mg
Number of subjects: 8
Study 15690266 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine 60 mg
Number of subjects: 8
Study 15690266 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal 2-chloroprocaine 10 mg to 60 mg
Number of subjects: 8
Study 12901778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Alzheimer's disease (n = 244)
Number of subjects: 1602
Study 12901778 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionable dementia (QD)
Number of subjects: 1602
Study 12901778 — intervention group
Group type: COMPARATOR
Intervention: Non-demented elderly controls
Number of subjects: 1602
Study 10485770 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon (43% at 0.6 MAC) and isoflurane (0.5% at 0.4 MAC)
Number of subjects: 15
Study 10485770 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (1.2%)
Number of subjects: 15
Study 10485770 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (63% at 0.6 MAC) and isoflurane (0.5%)
Number of subjects: 15
Study 7573470 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of H2SO4 aerosol (1,000 microgram/m3)
Number of subjects: 12
Study 7573470 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of NaCl aerosol (control)
Number of subjects: 12
Study 1949257 — intervention group
Group type: EXPERIMENTAL
Intervention: LongoVital (LV)
Number of subjects: 29
Study 1949257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 7262013 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal stimuli (mono-syllabic words, either 'neutral' or 'emotional')
Number of subjects: 8
Study 7262013 — intervention group
Group type: EXPERIMENTAL
Intervention: Tones (400 Hz)
Number of subjects: 8
Study 31286921 — intervention group
Group type: EXPERIMENTAL
Intervention: Justa cookstove intervention
Number of subjects: 230
Study 31286921 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional wood-burning cookstove)
Number of subjects: 230
Study 29016185 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Protein Solution (APS)
Number of subjects: 46
Study 29016185 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 46
Study 26752690 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 784
Study 26752690 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (BP) z-score
Number of subjects: 784
Study 26752690 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose control
Number of subjects: 784
Study 26752690 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HDL
Number of subjects: 784
Study 26752690 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) z-score
Number of subjects: 784
Study 26752690 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity C-reactive protein (CRP)
Number of subjects: 784
Study 24706091 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP)
Number of subjects: 385
Study 24706091 — intervention group
Group type: COMPARATOR
Intervention: Search AV+ (SAV+)
Number of subjects: 385
Study 22709422 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme for chronic skin diseases (12-week duration)
Number of subjects: 50
Study 22709422 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 50
Study 19636555 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral leucovorin (LV) at a single dose of 25 mg administered 4 hours before surgery
Number of subjects: 60
Study 19636555 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral leucovorin (LV) at a single dose of 25 mg administered 12 hours before surgery
Number of subjects: 60
Study 19636555 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral leucovorin (LV) at a single dose of 25 mg administered 18 hours before surgery
Number of subjects: 60
Study 19636555 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LV administration)
Number of subjects: 60
Study 19022974 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal protein-energy supplementation during pregnancy
Number of subjects: 1270
Study 15800692 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency coagulation
Number of subjects: 240
Study 15800692 — intervention group
Group type: COMPARATOR
Intervention: Rubber band ligation
Number of subjects: 240
Study 15265397 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal injection of pirarubicin
Number of subjects: 68
Study 10875855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganirelix
Number of subjects: 730
Study 10875855 — intervention group
Group type: COMPARATOR
Intervention: Buserelin (control)
Number of subjects: 730
Study 9289671 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estriol
Number of subjects: 30
Study 9289671 — intervention group
Group type: COMPARATOR
Intervention: Ethinyl‐estradiol
Number of subjects: 30
Study 9289671 — intervention group
Group type: COMPARATOR
Intervention: Bromhexine associated with gonadotropins
Number of subjects: 30
Study 1553933 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine treatment
Number of subjects: 28
Study 1553933 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28
Study 3158675 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine 200 mg/24 hours for 10 days
Number of subjects: 12
Study 3158675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.5 and 1.0 g/kg of body weight
Number of subjects: 12
Study 3158675 — intervention group
Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 12
Study 30597039 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating vitamin D concentrations (25(OH)D)
Number of subjects: 73769
Study 29747432 — intervention group
Group type: EXPERIMENTAL
Intervention: Mangosteen extract with behavioral therapy
Number of subjects: 22
Study 29747432 — intervention group
Group type: COMPARATOR
Intervention: Behavioral therapy alone
Number of subjects: 22
Study 27174904 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14171
Study 27174904 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14171
Study 24885585 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 hours of intensive attention training by Attention Process Training
Number of subjects: 120
Study 24885585 — intervention group
Group type: COMPARATOR
Intervention: Standard, activity based training
Number of subjects: 120
Study 22753219 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193
Study 22753219 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9193
Study 20225393 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAglyCD3
Number of subjects: 80
Study 20225393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18398592 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate endpoint trials
Number of subjects: 0
Study 15993231 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol eye drops
Number of subjects: 326
Study 15993231 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 326
Study 12814445 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose insulin (6 pmol min-1) + C-peptide (2-60 pmol min-1)
Number of subjects: 11
Study 12814445 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose insulin (30 pmol min-1) + C-peptide
Number of subjects: 11
Study 12814445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 12814445 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide (during low dose insulin)
Number of subjects: 11
Study 9808805 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile group
Number of subjects: 958
Study 7482389 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 0
Study 7482389 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection for the INDANA project
Number of subjects: 0
Study 7482389 — intervention group
Group type: EXPERIMENTAL
Intervention: Main analysis of the INDANA project
Number of subjects: 0
Study 2568765 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine (L)
Number of subjects: 23
Study 2568765 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 23
Study 23018 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 0
Study 23018 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0
Study 23018 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 0
Study 30011318 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal milk supplementation (MMS) with a breastfeeding support program
Number of subjects: 204
Study 30011318 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 204
Study 27295488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-kicking balance-perturbation training (BPT); single 30-minute session
Number of subjects: 44
Study 27295488 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG); no intervention
Number of subjects: 44
Study 24786979 — intervention group
Group type: EXPERIMENTAL
Intervention: High left ventricular pacing threshold (LVPT) >1.8 V
Number of subjects: 975
Study 24786979 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile LVPT
Number of subjects: 975
Study 24786979 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 volt increase in LVPT
Number of subjects: 975
Study 22566414 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall intervention for boys (RCT)
Number of subjects: 529
Study 22566414 — intervention group
Group type: COMPARATOR
Intervention: Usual care for boys (Control)
Number of subjects: 529
Study 22566414 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration study for girls
Number of subjects: 529
Study 20889523 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamins C and E (1000 mg vitamin C and 400 IU RRR α-tocopherol daily)
Number of subjects: 643
Study 20889523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 18473176 — intervention group
Group type: EXPERIMENTAL
Intervention: Water (200 ml)
Number of subjects: 12
Study 18473176 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 12
Study 18473176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 12
Study 18473176 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 12